- Home
- CANF
as 12-20-2024 4:00pm EST
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
| Founded: | 1994 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 14.4M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.29 - $4.69 | Next Earning Date: | 12-31-2024 |
| Revenue: | $667,000 | Revenue Growth: | -15.89% |
| Revenue Growth (this year): | 409.56% | Revenue Growth (next year): | N/A |
Latest Can-Fite Biopharma Ltd Sponsored ADR (Israel) News
CANF Breaking Stock News: Dive into CANF Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
GlobeNewswire
19 days ago
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
ACCESSWIRE
a month ago
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
MT Newswires
a month ago
Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer
GlobeNewswire
a month ago
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
TipRanks
2 months ago
Can-Fite BioPharma Secures Australian Patent for Obesity Drug
GlobeNewswire
2 months ago
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
MT Newswires
2 months ago
Can-Fite BioPharma's Partner Reports Positive Study Results of Piclidenoson in Dogs With Osteoarthritis
Compare CANF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.